General Information of Drug (ID: DMB8T5U)

Drug Name
ONT-093 Drug Info
Synonyms MDR inhibitors, Ontogen; OC-144-093
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
6450807
CAS Number
CAS 216227-54-2
TTD Drug ID
DMB8T5U

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
EDP-322 DMWTVM1 Bacterial infection 1A00-1C4Z Phase 1 [3]
W-198 DMJ2R69 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
LY335979 DM2KITF Acute myeloid leukaemia 2A60 Discontinued in Phase 3 [5]
CBT-1 DM097UP Non-small-cell lung cancer 2C25.Y Discontinued in Phase 3 [6]
Biricodar DM65JCM Ovarian cancer 2C73 Discontinued in Phase 2 [7]
Tariquidar DMJG7VP Adrenocortical carcinoma 2D11.Z Discontinued in Phase 2 [8]
Elacridar DMURVE8 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [9]
TRISMETHOXYRESVERATROL DM6USPC Discovery agent N.A. Investigative [10]
[1,1':2',1'']-terphenyl-4,3'',5''-triol DMVOY4D Discovery agent N.A. Investigative [10]
XR-9456 DMTUFI1 Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Multidrug resistance protein 1 (ABCB1) TT3OT40 MDR1_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011621)
2 A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23(4):311-5.
3 In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. J Antimicrob Chemother. 2015 Jan;70(1):173-7.
4 Mechanisms of tetrandrine and 5-bromotetrandrine in reversing multidrug resistance may relate to down-regulation of multidrug resistance associated protein 7 expression. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20(3):558-63.
5 A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxoru... Clin Cancer Res. 2004 May 15;10(10):3265-72.
6 A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors. Oncologist.2012;17(4):512.
7 ClinicalTrials.gov (NCT00003847) VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer. U.S. National Institutes of Health.
8 Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Biochem Pharmacol.2008 Mar 15;75(6):1302-12.
9 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties. J Med Chem. 2008 Dec 11;51(23):7602-13.
10 Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
11 Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.